OmniAb, Inc. (OABI)

How it makes money

Revenue comes from four sources tied to a partner's drug-development timeline: upfront or annual platform access fees, payments for research services performed, milestone payments triggered by preclinical, clinical or regulatory events, and royalties on sales once a partner's drug reaches the market. Near-term revenue leans on fees and milestones; the royalty stream — the largest potential prize — only grows once partner drugs are approved and selling.

The platform rests on proprietary transgenic animals not available elsewhere, protected by 29 issued U.S. patents expiring between 2028 and 2039, plus a specialized capability in ion-channel targets that the company says is underserved by competitors. Rivals include both large pharmaceutical players and other discovery-technology firms using different methods such as phage or yeast display.

Demand depends on biotech and pharma partners' willingness to fund early-stage drug discovery, which tends to slow when biotech financing conditions tighten. With 107 partners and 407 programs spread across many companies and disease areas, no single partner's decision should move results as much as a downturn across biotech funding broadly would.

Key risks

• No control over partner decisions — OmniAb does not control the development timeline, regulatory strategy or commercialization decisions of its partners, so its own results depend on choices made by other companies.
• Milestone and royalty timing is uncertain — Significant uncertainty surrounds whether and when partner programs reach regulatory approval, and royalty payments may never become a material source of revenue if they don't.
• Competitive discovery-technology market — The antibody discovery platform market is highly competitive, with rivals ranging from established pharmaceutical companies to biotech firms using alternative discovery methods.
• Healthcare policy pressure on royalties — Regulation such as the U.S. Inflation Reduction Act imposes added pricing and regulatory burdens on drugmakers, which could reduce partner profitability and, in turn, the royalties OmniAb collects.
• Patent protection is time-limited — Core patents expire between 2028 and 2039, extensions are not guaranteed, and competitors may design around the protected technology before then.

OmniAb does not disclose a specific revenue percentage for its largest partner in the sections reviewed; the base is described as 107 active partners rather than a handful of dominant ones.